>
Organization
Novartis Corporation
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed

News on Novartis Corporation

... 1999. Prior to this, he was President and Chief Executive Officer of Novartis Corporation, the US subsidiary of Novartis AG. Mr. Watson's career spanned 33 ...
... away from the injectable DMTs, in particular Teva's Copaxone, and moved towards Novartis' Gilenya, Biogen's Tysabri, and Genentech's Ocrevus. Following recent quarter-over-quarter increases, reported first-line ...
... in support of their evaluation of the health and economic outcomes of Novartis's Mayzent (siponimod) for the treatment of secondary progressive multiple sclerosis (SPMS). According ...
... Mrs. King joined NEA after serving as a Senior Vice President of Novartis Corporation. Before Novartis, Mrs. King spent ten years with Genetic Therapy, Inc. ...
... experience, as well as broad access across countries. With Sanofi's Aubagio and Novartis' Gilenya shares remaining flat, significant increases in Mavenclad trial and adoption in ...
... past year, the new start oral DMT class share, including Genzyme's Aubagio, Novartis' Gilenya, and Biogen's Tecfidera, has remained stable with the prior audit. Instead, ...
... of bringing safe, effective products to patients," explains Vivianne Arencibia, Global Head, Novartis Quality External Engagement. DIA NOW will enable access to curated content customized ...
... vice president of Global Solutions for LinkedIn; Robert Pelzer, former president of Novartis Corporation; Matthew Ray, founder and managing partner of Portage Point Partners; and ...
... growth. Mavenclad, primarily prescribed to relapsing-remitting MS (RRMS) patients, is competing with Novartis' Gilenya and monoclonal antibody (mAb) DMTs, such as Roche's Ocrevus, Sanofi's Lemtrada, ...
... Ms. Boudreau held a variety of leadership roles with increasing responsibility at Novartis, including serving as the Chief Financial Officer of Novartis Corporation, the U.S. ...
Subscribe now for full coverage on Novartis Corporation
Start My Free Trial